Clinical Trials Logo

Filter by:
NCT ID: NCT05111314 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Start date: February 11, 2022
Phase: Early Phase 1
Study type: Interventional

This phase 0/1 study evaluates intraarterial administration of gallium Ga 68 gozetotide (68Ga-PSMA) for the detection of prostate-specific membrane antigen (PSMA) positive liver cancer by positron emission tomography (PET)/computed tomography (CT). 68Ga-PSMA is an imaging agent used with PET/CT scans to locate PSMA positive lesions. This study evaluates intraarterial administration of this agent, compared to intravenous administration.

NCT ID: NCT05109052 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Start date: September 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will assess the safety and tolerability of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab in unresectable or metastatic hepatocellular carcinoma. Phase 2 will assess the efficacy of this combination therapy in unresectable or metastatic hepatocellular carcinoma.

NCT ID: NCT05107791 Withdrawn - Clinical trials for Accommodation Disorder

Effects of Stulln and Accommodative Training

Start date: March 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The present study tests the hypothesis that Stulln eyedrops improve accommodative functions by improving the short term facility of ciliary muscles that can be transferred into long-term adaptation. To test this, the investigators propose to conduct a prospective randomized control trials where participants with accommodative dysfunctions are randomly assigned to four groups: control, Stulln only and Stulln plus vision training. The investigators' theory predicts that the efficacy of Stulln will be augmented by vision training.

NCT ID: NCT05107427 Withdrawn - Clinical trials for Urothelial Carcinoma

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

AVENU
Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, switch maintenance study of MRx0518 and Avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) whose disease did not progress after 4 to 6 cycles of first-line platinum-containing chemotherapy and who have residual measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Up to 30 patients will be enrolled. Patients enrolled in this study will be treated with IV Avelumab every 2 weeks and MRx0518 daily during the treatment period. Patients will receive the study treatment until disease progression (PD), patient withdrawal, or unacceptable toxicity.

NCT ID: NCT05105061 Withdrawn - Suicidal Ideation Clinical Trials

Intramuscular Ketamine for Suicidal Ideation

Start date: February 2022
Phase: Phase 2
Study type: Interventional

The objective of the present research protocol, a cross-over, subject-blinded, clinical trial, is to correlate changes in brain activity with reduction in suicidal ideation in response to a single intramuscular dose of ketamine. While ketamine is increasingly used as a rapid, antidepressant agent, there is accumulating evidence of additional anti-suicidal properties that may be distinct from its effects on depression. This pilot study will be used to determine (1) whether specific electroencephalogram (EEG) findings are correlated with response of SI to intramuscular (IM) ketamine, and (2) the effectiveness of IM ketamine in the treatment of acute SI.

NCT ID: NCT05104229 Withdrawn - Ulcerative Colitis Clinical Trials

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

SAVES-IBD
Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

Aim to determine if aspirin 81 mg orally twice daily is effective and safe as an extended VTE chemoprophylaxis agent after major abdominal surgery for IBD patients. Study will perform an open label trial of aspirin for VTE prophylaxis compared standard of care.

NCT ID: NCT05102461 Withdrawn - Dysbiosis Clinical Trials

Monitoring the Effects of Probiotic Supplementation in Immunocompromised Kidney Transplanted Subjects

Start date: July 2020
Phase: N/A
Study type: Interventional

In order to protect their new renal graft, post-transplant patients follow a rigorous immunosuppressive therapy combined with prophylactic antibiotic treatment. Kidney transplant recipients are prescribed long-term immunosuppression maintenance regimens that are the prophylaxis of organ rejection. The most frequently used are calcineurin inhibitors (tacrolimus or cyclosporine) combined with glucocorticoids (methylprednisolone, prednisone) and antiproliferative agents (mycophenolate mofetil, azathioprine). However, the use of immunosuppressive medication in transplanted patients have well-documented limitations. Recent studies reported major changes in microbiota composition as a result of immunosuppression use. A large majority of transplant patients develops severe GI problems, with the most common complication being post-transplant diarrhea. Several studies have assessed and confirmed negative effects of post-transplant diarrhea. According to (3, 4), post-transplant diarrhea affects 1 in 5 patients in the first year after kidney transplantation and is associated with decreased quality of life, allograft failure, and even death.

NCT ID: NCT05102071 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Start date: November 1, 2021
Phase:
Study type: Observational

Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin versus patients on sulfonylureas as an add-on therapy to metformin in patients with Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD).

NCT ID: NCT05100160 Withdrawn - Pulmonary Disease Clinical Trials

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

The aim of this study is to determine if the reduction in narcotic requirement following pulmonary resection with gabapentin is clinically significant when compared to the effect seen with placebo. We have defined clinically meaningful as a reduction by 30 Morphine equivalent doses (MED)

NCT ID: NCT05099952 Withdrawn - Clinical trials for Head and Neck Squamous Cell Carcinoma

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

Start date: December 15, 2021
Phase: N/A
Study type: Interventional

This clinical trial studies the effect and underlying mechanisms of sleep and circadian rhythm factors on oral mucositis pain in head and neck cancer patients treated by chemoradiotherapy. Poor sleep may have a correlation to increased pain. A behavioral intervention, Brief Behavioral Therapy for Cancer related Insomnia, may improve patients' sleep and may also reduce oral mucositis pain.